AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01771328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
Study NCT01771328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone acetate
Description: Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
Study NCT00790764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MESENDO
Description: For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
Study NCT00790764 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
Study NCT02593409 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TDF/FTC
Description: All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
Study NCT04308772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Physiotherapy
Description: Participants will receive an exercise programme, based on those patients usually get in the form of an exercise leaflet, delivered via a web-based physio website (www.giraffehealth.com). Participants will be asked to complete their exercise programme as prescribed (at least once each day) and to fill out an online exercise diary which the physiotherapist can see remotely from the clinical site.
Study NCT04355910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie restriction
Description: Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat.
Study NCT04355910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat.
Study NCT01814202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTM202
Study NCT01814202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04600232 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Alere TB-LAM
Description: Subjects also undergo clinical evaluation including CT, sputum smear, Gene Xpert and mycobacterial culture.
Study NCT00558337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa-carbidopa
Description: novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
Study NCT01333163 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human GLP-1 (7-36) amide
Description: 2 hour IV infusion, 1,5pmol/min/kg.
Study NCT01333163 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Isotone NaCl
Description: 2 hours IV infusion.
Study NCT01619150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etoricoxib, followed by placebo (matching tablet, without active ingredient)
Description: Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
Study NCT01619150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (matching tablet, without active ingredient), followed by etoricoxib
Description: Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
Study NCT02095951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol lock therapy (ELT)
Description: Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
Study NCT02095951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol lock therapy (ELT)
Description: Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
Study NCT05019378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF treatment
Description: autologous SVF (10E8 cells)
Study NCT02851927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini Thoracoscopy
Description: Pleural biopsy using rigid mini thoracoscope
Study NCT02851927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SemiRigid Thoracoscopy
Description: Pleural biopsy using semirigid thoracoscope
Study NCT02938533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
Study NCT02729428 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo an MRI scan
Study NCT02208999 — intervention group
Intervention type: DEVICE
Intervention: Neurostimulator Precision
Description: All patients included must have been implanted with the neurostimulator Precision
Study NCT02652871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase.
Study NCT02652871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.
Study NCT02652871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age \< 60 years). In patients > 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days.
Study NCT03293693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5 g beta-glucan
Description: Dietary cross-over study with beta-glucan fiber
Study NCT03293693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3.5 g beta-glucan
Description: Dietary cross-over study with beta-glucan fiber
Study NCT03293693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8 g beta-glucan
Description: Dietary cross-over study with beta-glucan fiber
Study NCT00671944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein diet
Description: Low protein diet for 6.5 weeks
Study NCT02369770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stretching and active movement training
Description: A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.
Study NCT02910154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet
Description: Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician
Study NCT02910154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.
Study NCT02910154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication (with statin and ACE-inhibition)
Description: Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure > 130 and/or low density lipoprotein (LDL) > 2.0.
Study NCT02995577 — intervention group
Intervention type: OTHER
Intervention: Feeding tolerant
Study NCT02995577 — intervention group
Intervention type: OTHER
Intervention: Feeding intolerant
Study NCT00937313 — intervention group
Intervention type: OTHER
Intervention: Champagne wine intervention
Description: Placebo-controlled randomised cross-over human trial
Study NCT02995577 — intervention group
Intervention type: OTHER
Intervention: Necrotizing enterocolitis
Study NCT01324440 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V710 (30 µg) with MAA
Description: Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
Study NCT01324440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 (30 µg) without MAA
Description: Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
Study NCT01669876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anatabloc(R)
Description: Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
Study NCT01669876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
Study NCT04532138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VS-CMAC Rigid Fiberoptic Stylet
Description: patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
Study NCT04532138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC Video laryngoscope awake intubation
Description: patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using C-MAC Video Laryngoscope intubation.
Study NCT00284986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochymal®
Description: Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells
Study NCT01139060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: organized care program for chronic or recurrent depression
Study NCT04293380 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: amniosyntesis
Study NCT02665637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Each patient may receive single dose by intravenous infusion
Study NCT02838693 — intervention group
Intervention type: PROCEDURE
Intervention: Not applicable. This is an observational study.
Description: Not applicable. This is an observational study.
Study NCT04578769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional myotomy
Description: 1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips.
Study NCT04578769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: short myotomy
Description: 1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 6 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips.
Study NCT04578769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full-thickness myotomy
Description: 1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 4 cm proximal to the GEJ, and a full-thickness muscle myotomy is continually carried out from 4cm proximal to the GEJ down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips.
Study NCT04578769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tailored myotomy
Description: 1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 2 cm proximal to the spastic segment within the esophageal body, which is identified based on information gained from high-resolution manometry (HRM).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips.
Study NCT01502631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUN13837 injection
Description: SUN13837 injection, injection 1 x daily for 28 doses
Study NCT01502631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, volume equivalent to injection 1 x daily for 28 doses
Study NCT00699920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coarsucam
Description: Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
Study NCT00699920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
Study NCT03686319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology: foot massage
Study NCT01821716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prick test Dermatophagoides pteronyssinus allergen extract
Description: This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
Study NCT00622349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Ifosfamide, Gemcitabine
Description: Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
Study NCT00622349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide, Gemcitabine
Description: Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
Study NCT00622349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, docetaxel
Description: Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
Study NCT01166867 — intervention group
Intervention type: DEVICE
Intervention: Photo-plethysmography monitoring
Description: monitoring vital sign in infant
Study NCT02447367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1207(Fasted)
Description: Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.
Study NCT02447367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1207(Fed)
Description: Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
Study NCT01249274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 100mgs progesterone twice daily
Study NCT01249274 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo pills to be taken twice daily
Study NCT01734174 — intervention group
Intervention type: PROCEDURE
Intervention: transesophageal echocardiography (TEE)
Description: Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
Study NCT01734174 — intervention group
Intervention type: PROCEDURE
Intervention: thermodilution
Description: A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Initial serum malondialdehyde level
Description: Blood sample (0.4ml) will be obtained within 5 minutes before induction of general anaesthesia.~Samples will be obtained in both groups (LAE and OAE)
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Final serum malondialdehyde level
Description: Blood sample (0.4ml) will be obtained within 5 minutes after wound closure. Samples will be obtained in both groups (LAE and OAE)
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Initial differential white blood cell count
Description: Differential blood counts (microscopic) will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE).
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Final differential white blood cell count
Description: Differential blood counts (microscopic) will be obtained 24h after the first sample (Initial differential blood count).~Samples will be obtained in both groups (LAE and OAE).
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Initial c-reactive protein serum level
Description: C-reactive protein levels will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE).
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Final c-reactive protein serum level
Description: C-reactive protein levels will be obtained 24h after the first sample (initial c-reactive protein level).~Samples will be obtained in both groups (LAE and OAE).
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Initial VOC
Description: Volatile organic compound sampling (2 samples within 5 minutes) within 10 minutes before induction of general anesthesia
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 5min
Description: Volatile organic compound sampling (2 samples within5 minutes) within 5 minutes after endotracheal intubation before skin incision.
Study NCT01734174 — intervention group
Intervention type: PROCEDURE
Intervention: transthoracic echocardiography (TTE)
Description: Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
Study NCT03258164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASC enriched lipofilling
Description: Fat grafts enriched with ex vivo expanded ASC